EI 15072

Drug Profile

EI 15072

Latest Information Update: 10 Nov 2006

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Caspase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Rheumatoid arthritis; Shock

Most Recent Events

  • 08 Jun 2001 No-Development-Reported for Shock in Japan (Unknown route)
  • 08 Jun 2001 No-Development-Reported for Rheumatoid arthritis in Japan (Unknown route)
  • 08 Jun 2001 No-Development-Reported for Inflammation in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top